Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals

VRTX

Vertex Pharmaceuticals Incorporated NASDAQ

$468.42 ▲ 0.35%
VS

REGN

Regeneron Pharmaceuticals, Inc. NASDAQ

$618.03 ▲ 0.90%
Last updated: (23h 37m ago) • VRTX at $468.42, REGN at $618.03
CleaRank Financial AI • Data from TwelveData & CoinGecko
Reviewed by CleaRank editorial team. Data refreshed daily. Not financial advice.

Comparative Analysis

Vertex Pharmaceuticals (VRTX) emerges as the stronger contender over Regeneron Pharmaceuticals (REGN) based on current data. VRTX demonstrates superior profitability and a more robust technical setup, indicating a stronger current market position. While REGN shows higher revenue growth, VRTX's efficiency in converting revenue to profit and its more favorable technical indicators suggest a more compelling investment profile at this juncture. Investors seeking a blend of solid financial performance and positive momentum should favor VRTX.

Key Differentiator

The decisive factor favoring Vertex Pharmaceuticals (VRTX) is its superior profitability and robust technical setup. VRTX's ability to generate higher margins and returns on equity, coupled with its price trading above key moving averages and positive momentum indicators, presents a more compelling investment case than REGN's higher revenue growth offset by lower profitability and weaker technicals.

Joint Outlook

For Vertex Pharmaceuticals (VRTX), the outlook remains positive, supported by its strong profitability and current technical momentum. Continued success in its pipeline and sustained revenue growth could see the stock test higher levels, potentially challenging its 52-week high. However, a shift in market sentiment or unexpected clinical trial results could lead to a correction. Regeneron Pharmaceuticals (REGN) faces a more uncertain outlook. Its higher revenue growth is a positive, but if profitability does not improve and its technical downtrend persists, it may struggle to regain upward momentum. A catalyst from new drug approvals or significant market share gains would be needed for a strong recovery.

Price Analysis Comparison

Valuation Metrics i

MetricVRTXREGN
P/E Ratio 27.70 15.08
Market Cap 118.89B 64.79B
Price/Sales 9.70 4.34
Price/Book 6.13 2.00
EV/EBITDA 22.73 12.97
Dividend Yield N/A N/A
Vertex Pharmaceuticals (VRTX) trades at a P/E ratio of 27.7, which is higher than Regeneron Pharmaceuticals (REGN) at 14.9. However, VRTX's higher P/E is justified by its significantly stronger profitability metrics. REGN's lower P/E might suggest a value opportunity, but it comes with lower returns on equity and assets. VRTX's valuation, while appearing richer on a P/E basis, reflects its superior operational efficiency and profitability.

Profitability & Efficiency i

MetricVRTXREGN
Rev. Growth (Qtly) 7.80% 19.00%
Profit Margin 35.51% 29.65%
Return on Equity 24.20% 14.55%
Return on Assets 12.14% 6.13%
Debt/Equity 10.26 8.61
Vertex Pharmaceuticals (VRTX) significantly outperforms Regeneron Pharmaceuticals (REGN) in profitability. VRTX boasts a net profit margin of 35.51%, a return on equity of 24.2%, and a return on assets of 12.14%. REGN's figures are notably lower, with a net profit margin of 29.65%, a return on equity of 14.55%, and a return on assets of 6.13%. VRTX demonstrates superior capital efficiency and earnings power.

Earnings Reality Check i

VRTX

Analysis loading...

REGN

Analysis loading...

Technical Indicators

IndicatorVRTXREGN
RSI (14) 75.15 57.09
50-Day MA $439.11 $674.31
200-Day MA $440.34 $697.57
Vertex Pharmaceuticals (VRTX) presents a stronger technical picture. Its RSI of 64.51 indicates robust momentum, nearing but not yet in overbought territory. The MACD at 5.26 suggests an upward trend. VRTX is trading above both its 50-day ($438.46) and 200-day ($439.98) moving averages, confirming support. Regeneron Pharmaceuticals (REGN) shows a more mixed technical profile, with an RSI of 55.74 and a negative MACD of -18.25, indicating weaker momentum. REGN is trading below its 50-day ($676.93) and 200-day ($697.31) moving averages, suggesting it is in a resistance zone.

AI Analyst Sentiment

VRTX

Buy
Technical Score: 75/100

REGN

Hold
Technical Score: 55/100
While specific institutional and insider data is not provided, the technical indicators offer a proxy for market sentiment. VRTX's strong upward technical signals, including its position above key moving averages and positive MACD, suggest favorable institutional positioning and investor confidence. REGN's weaker technicals, trading below its longer-term averages and exhibiting a negative MACD, imply a more cautious or bearish sentiment from market participants.

Risk Stratification i

MetricVRTXREGN
Beta (Volatility) i 0.31 0.24
Sharpe Ratio 0.26 -0.47
Vertex Pharmaceuticals (VRTX) faces the risk of its high valuation becoming unsustainable if revenue growth falters or if its pipeline drugs face unexpected clinical setbacks. Its current technical strength also means it could be susceptible to a sharp pullback if market sentiment shifts. Regeneron Pharmaceuticals (REGN) carries the risk associated with its lower profitability and weaker technical trend; a failure to accelerate revenue growth or improve margins could lead to further price depreciation. Its position below key moving averages suggests it may struggle to break out of its current trading range.

Comparative ProTips

  • Prioritize VRTX for its superior profitability and stronger technical trend, despite a higher P/E.
  • Monitor REGN's revenue growth acceleration and margin improvement for potential turnaround signals.
  • Consider VRTX's current technical strength as a confirmation of positive market sentiment, but be mindful of potential overbought conditions if RSI approaches 70.

Monte Carlo Projection (10yr)

Actionable Trade Plans

Compare entry, exit, and risk management levels for both assets

Select Your Trade Bias
Risk Tolerance
Conservative 3% Aggressive
Portfolio Value
$ ✎
Position Size: $200 - $300 per asset
VRTX
Current: $468.42
ENTRY ZONES
Conservative
$445.00
Aggressive
$468.42
RISK MANAGEMENT
STOP LOSS
$431.65
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$467.25
+10%
$489.50
+15%
$511.75
REGN
Current: $618.03
ENTRY ZONES
Conservative
$587.13
Aggressive
$618.03
RISK MANAGEMENT
STOP LOSS
$569.51
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$616.48
+10%
$645.84
+15%
$675.20
ℹ️ Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss.

Note: The AI favored VRTX based on current technical setup. This is valid for the specified timeframe only.

Frequently Asked Questions

Which stock, VRTX or REGN, offers better value based on P/E ratio? +
REGN offers a lower P/E ratio (14.9) compared to VRTX (27.7), suggesting REGN might appear more attractively valued on this metric alone. However, VRTX's higher P/E is supported by its significantly superior profitability.
What is the revenue growth comparison between VRTX and REGN as of June 2026? +
REGN shows stronger revenue growth at 19%, outpacing VRTX's 7.8% growth. This indicates REGN is expanding its top line at a faster pace.
How do VRTX and REGN compare in terms of profitability metrics? +
VRTX demonstrates superior profitability with a net profit margin of 35.51%, ROE of 24.2%, and ROA of 12.14%, significantly higher than REGN's 29.65% margin, 14.55% ROE, and 6.13% ROA.
What do the technical indicators suggest for VRTX versus REGN? +
VRTX exhibits stronger technicals with an RSI of 64.51, positive MACD, and price above its 50-day and 200-day moving averages. REGN's technicals are weaker, with an RSI of 55.74, negative MACD, and price below its key moving averages.
Is VRTX or REGN currently in a stronger uptrend based on moving averages? +
VRTX is in a stronger uptrend, trading above its 50-day ($438.46) and 200-day ($439.98) moving averages. REGN is trading below its 50-day ($676.93) and 200-day ($697.31) moving averages, indicating resistance.
Which stock is a better buy for momentum investors in June 2026? +
VRTX is the better buy for momentum investors due to its higher RSI (64.51) and positive MACD, indicating strong upward momentum. REGN's RSI (55.74) and negative MACD suggest weaker momentum.
What are the key risks for VRTX and REGN in the current market? +
VRTX risks include its high valuation and potential pipeline failures. REGN risks involve its lower profitability, weaker revenue growth acceleration, and current technical downtrend.
View all Healthcare sector assets Browse hub →

People Also Watch

COIN vs HOOD
COIN vs HOOD Comparison
$151.30 -4.35%
AMAT vs LRCX
AMAT vs LRCX Comparison
$576.03 -1.68%
LLY vs ABBV
LLY vs ABBV Comparison
$1,108.31 +0.1111%
WFC vs C
WFC vs C Comparison
$84.32 +0.2258%

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. This AI-generated comparison of VRTX vs REGN is for educational and informational purposes only and does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities or digital assets. The comparison metrics, trade plans, and AI signals are hypothetical, hindsight-based, and simulated. Different asset classes carry different risk profiles - stocks, ETFs, cryptocurrencies, commodities, and forex each have unique regulatory frameworks and risk factors. Market data is provided "as-is" and may be delayed by 15 minutes or more. Past performance does not guarantee future results. You should never invest money you cannot afford to lose. Consult a qualified financial advisor before making any investment decisions. Analysis generated on June 25, 2026.